iron 5 months later. $ In haemodialysis patients, both the mean haemo-While 15.3-21.7% of haemodialysis patients were clasglobin levels and the epoetin dose required to sified as having absolute iron deficiency, the percentage achieve these haemoglobin levels were significantly of peritoneal dialysis patients with absolute iron defidifferent across the three categories of iron status; ciency in any given month ranged from 40.9 to 44.5%. patients with adequate iron status reached a higher Table 14 shows monthly iron status for haemodialysis haemoglobin level with a lower epoetin dose. and peritoneal dialysis patients in the maintenance phase of epoetin therapy. Between 57.5 and 64.6% of The role of iron is crucial to red cell production and to the epoetin response, as the need for available iron haemodialysis patients had an adequate iron status in any given month, while 45.0-49.5% of peritoneal is increased due to enhanced erythropoietic activity [1, 2] . While underdialysis ( Kt/V <1.2) and poor dialysis patients had an adequate iron status.
Given the importance of serum ferritin as a marker nutritional status (based on low serum albumin concentrations) were identified in the 1997 ESRD Core of iron deficiency, we examined the distribution of month 6 serum ferritin levels for haemodialysis and Indicators Project paper as having a negative impact peritoneal dialysis patients ( Figure 13 ). The results Figure 16 ). Results for peritoneal dialysis patients are differ for the two modalities of dialysis. In the haemo-more difficult to interpret, as (somewhat surprisingly) dialysis patients who had valid month 6 data, 37.5% patients with absolute iron deficiency had slightly had serum ferritin levels of 200 mg/l or less. Of the higher haemoglobin values than did those with either peritoneal dialysis patients, 60.3% had ferritin levels in functional iron deficiency or adequate iron status (see this range. The haemodialysis patients were distributed bottom of Figure 17 ). The explanation for this more evenly across all serum ferritin categories. The unexpected finding remains unclear. observed difference in serum ferritin levels between Table 15 shows the numbers and percentages of both haemodialysis and peritoneal dialysis patients was stat-haemodialysis and peritoneal dialysis patients achievistically significant ( x2=334.797, df=7, P<0.001).
ing adequate iron status who had haemoglobin levels Bivariate distributions of hypochromic red cells by of ∏11.0 g/dl at months 1, 3 and 6. The percentage of haemoglobin, serum ferritin and TSAT are provided patients having adequate iron status in a given month for months 1, 3 and 6 in Figures 14 and 15 .
but who did not achieve a haemoglobin of at least 11.0 g/dl in that month ranged from 44.9 to 48.6% of haemodialysis patients and from 42.0 to 45.7% of
Iron status and haemoglobin
peritoneal dialysis patients. Differences in the distribution of patients achieving a haemoglobin of at least 11.0 g/dl between haemodialysis patients and peritonIn haemodialysis patients, both the mean haemoglobin eal dialysis patients were not significant for any month. levels and the epoetin dose required to achieve these When the definition of iron adequacy was modified to haemoglobin levels were significantly different across the three categories of iron status (see bottom of include the measurement of hypochromic red cells Figure 17 ). Again, in all red cell production, it might be expected that iron 3 months, the lowest epoetin doses were seen in patients deficiency would be associated with higher epoetin with adequate iron status. dose requirements. The mean epoetin doses used and
We also examined patients at the extremes of the the achieved haemoglobin levels are shown in Table 16 iron status continuum, specifically those with optimal and in Figures 16 and 17 . For months 1, 3 and 6, iron status (serum ferritin between 200 and 500 mg/l significant differences in epoetin dose were observed and TSAT between 30 and 40%), and those with among the three iron status categories for haemodialysis patients (month 1: F=24.74, df=2, 7461, inadequate iron status (serum ferritin <100 mg/l ) with oral iron, but patients receiving epoetin will 3 and 6 require i.v. iron supplementation.
The use of iron supplementation in ESAM is shown and 34% of peritoneal dialysis patients received no
iron supplementation during the 6 months of the study, while~80% of haemodialysis and 66% of peritoneal Changes in the route of iron supplementation for haemodialysis and peritoneal dialysis patients differed aAdequate iron status was defined as serum ferritin of Á100 mg/ l and TSAT of Á20%.
significantly from months 1 to 6, as shown in Table 19 . For haemodialysis patients, the percentage of patients in the 'no iron' group increased from month 1 (39.8%) status should be monitored every 3-6 months ( EBPG to month 6 (44.2%), while both the i.v. iron and oral 7B). Figure 19 shows the frequency of iron monitoring iron groups decreased. For the peritoneal dialysis for patients in both the correction and the maintenance group, however, the percentage of patients receiving phases of epoetin therapy; 41% of patients starting no iron remained fairly constant (50.0% at month 1 epoetin therapy had their iron status monitored less to 48.7% at month 6), while the percentage of patients frequently than is recommended by EBPG (for a receiving i.v. iron supplementation showed a slight description of the definition of correction and mainten-increase. 
Iron supplementation
who received iron supplementation throughout all 6 months of the survey with those who received no iron EBPG 8B states that almost every haemodialysis during this period. Haemodialysis patients generally patient will require at least one dose of i.v. iron every showed less absolute iron deficiency compared with 2 weeks. Furthermore, peritoneal dialysis patients not peritoneal dialysis patients, and they also had a higher proportion of adequate iron status. In both groups, receiving epoetin may have their iron stores maintained The sample includes only subjects with valid iron data at all 6months. aI.v. iron all 6 months and oral iron all 6 months are subcategories of iron in all 6 months. of the sample). The same analysis was done in peritoneal dialysis patients ( Figure 24) , and results were sim- sample were still receiving no iron at month 2, 83.6% were receiving no iron supplementation at month 3, Table 18 . Results of paired t-tests for differences between means: 70.4% were receiving no iron at month 4, 65.2% were haemoglobin month 1 vs month 6, epoetin dose month 1 vs month 6 receiving no iron at month 5 and 63.2% were receiving no iron at month 6.
Haemoglobin Epoetin dose Figure 25 shows data from three cohorts of patients: major effect of adequacy of iron status is reflected
P<0.01 P=NS
more in the epoetin dose requirements rather than in the mean haemoglobin achieved. The problem also with this type of analysis is that it is difficult to know there were no obvious differences between the two cohorts of patients who received continuous iron and whether patients with absolute iron deficiency receiving i.v. iron are being prescribed the i.v. iron as a result those who received no iron during all 6 months. Figures  23 and 24 compare patients who received only oral of absolute iron deficiency (which would seem more likely), rather than developing absolute iron deficiency iron for all 6 months with those who received i.v. iron for all 6 months. The patterns of distribution are while on i.v. iron. clearly different for haemodialysis and peritoneal dialysis patients. Haemodialysis patients who received
Infection and iron supplementation
only oral iron had a much higher incidence of absolute iron deficiency (~40% of the sample). A much lower incidence of absolute iron deficiency,~10-20%, In addition to haemoglobin and epoetin dose requirements, other outcomes of iron supplementation were occurred in those haemodialysis patients receiving i.v. iron continuously throughout the 6-month period. examined, including the development of infections. Of those patients taking iron supplementation, oral and There was also a much higher incidence of adequate i.v. administration routes were associated with similar [except in month 5 when patients receiving i.v. iron doses Á300 mg/month had an infection rate of 7.8% infection rates ( Figure 26 ). When the number of i.v. iron administrations per month was evaluated, there compared with 5.7% for those receiving i.v. iron doses ∏100 mg/month ( x2=5.06, df=1, P<0.05)]. were no differences in the monthly infection rates between those who received Á9 and those who received Figure 27 displays the incidence of infections in relation to the patients' serum ferritin levels. Three ∏2 administrations of i.v. iron. Similarly, differences in infection rates between patients receiving doses of cohorts of patients were examined: (i) those with a serum ferritin <500 mg/l; (ii) those with a ferritin i.v. iron of Á300 mg/month versus those receiving ∏100 mg/month were not statistically significant between 500 and 800 mg/l; and (iii) those with a serum aThe relationship is significant at P<0.001 for both haemodialysis and peritoneal dialysis.
ferritin >800 mg/l. The majority of patients had no While it is now well established that iron deficiency infections reported, while~10% of patients reported is one of the most common causes of a suboptimal one infectious complication. There were very small response to epoetin, and i.v. iron is effective in enhannumbers of patients developing more than one infec-cing the erythropoietic response, it remains unclear tion throughout the 6-month survey. There was no what the best parameters are for monitoring iron obvious relationship between the incidence of infec-status, and what should be the minimally acceptable tious disease and the serum ferritin, in that patients levels for such parameters. A serum ferritin level with iron overload (ferritin >800 mg/l ) did not seem >100 mg/l, TSAT >20% and hypochromic red cells to have any significant increase in the risk of infection. <10% are the most commonly quoted thresholds for adequate iron status [1, 2, 6 ] and, in order to achieve these levels in a population of renal failure patients, it
Comments has been suggested that ferritin levels of between 200 and 500 mg/l, TSAT levels of between 30 and 40% and hypochromic red cells <2.5% should be targeted [6 ] . Effective iron management arguably is as important to
The results shown in Table 14 suggest that there are the patient with renal anaemia as is administering significant differences in iron status between haemodiaepoetin therapy. There are two aspects to this topic: lysis and peritoneal dialysis patients. It would appear (i) monitoring iron status and reliably detecting absothat the proportion of haemodialysis patients with lute and functional iron deficiency; and (ii) adequate replacement with iron supplementation. adequate iron status is significantly greater than for peritoneal dialysis patients, the latter group having and 200 mg/l. It is also evident that the number of patients with iron overload (e.g. serum ferritin twice the proportion of patients with absolute iron deficiency (~40% compared with <20%). This is >1000 mg/l ) is now significantly lower than in former times when regular blood transfusions were given. almost certainly due to the greater use of intravenous iron in haemodialysis patients, as shown, for example, Clearly one might be less concerned if the patients who had inadequate iron status did in fact have adequate in Figure 20 .
Although the key messages regarding adequate iron haemoglobin concentrations. Figure 25 , however, indicates that the administration of iron is not related status have been well publicized over the last decade or so, it is of some concern to see that this is somewhat directly to achieved haemoglobin.
It is interesting that the patients who had regular lacking in so many patients in the survey, particularly since the deficit is so easily corrected. Figure 13 shows monitoring of hypochromic red cells generally had higher levels of haemoglobin, serum ferritin and TSAT, that just over 10% of haemodialysis and 30% of peritoneal dialysis patients have serum ferritin levels in association with a higher epoetin dose. The most likely explanation for this is that these data come from <100 mg/l at month 6, thus falling short of the recommendation in EBPG 6. A similar proportion of patients units in which the overall management of the patient is more intensely focused. Thus, it is not the has borderline adequate iron stores of between 100 measurement of hypochromic red cells per se that is tional iron deficiency), the percentage of hypochromic red cells increases. producing better results, but this is acting as a marker for 'good quality' units.
The frequency of iron monitoring was assessed in >14 500 patients in the survey (Figure 19) , and there It is not particularly surprising that there is no correlation between serum ferritin and the percentage is clearly some variability in this. The majority of units, however, seem to assess iron status every 4-6 weeks of hypochromic red cells. Serum ferritin is primarily a reflection of iron stores, whereas the percentage of in the correction phase of epoetin therapy, and either every 4-6 weeks or 9-12 weeks in patients in the hypochromic red cells reflects the presence of functional iron deficiency. This can occur at all levels of maintenance phase of treatment. There are still a large number of patients who are having their iron status serum ferritin, and the lack of any correlation has been found previously [7] . The significance of the weak assessed less frequently than is recommended by the EBPG. negative correlation between haemoglobin and percentage hypochromic red cells is difficult to explain, and
The data in Figure 20 confirm that the majority of patients receive iron supplementation for at least 1 its clinical significance is somewhat unclear. The negative correlation between transferrin saturation and month during the 6 months surveyed. It is perhaps of some concern that 18.7% of haemodialysis patients hypochromic red cells, seen in Figure 15 , is similar to that described previously [7] . This indicates that as the and 34.4% of peritoneal dialysis patients received no iron supplementation during the 6 months of percentage transferrin saturation decreases (in func- follow-up. This almost certainly represents suboptimal and i.v. iron is very limited, in line with the EPBG recommendations. There is no logic to this practice of anaemia management, and hopefully this will improve. It is also contrary to the EBPG, which suggest that joint use, since there will be negligible oral iron absorption in any patient receiving i.v. iron, and thus the almost all haemodialysis patients require at least one dose of i.v. iron every 2 weeks. Furthermore, in a patient is exposed to unnecessary gastrointestinal side effects. As expected, most of the haemodialysis patients nationally representative database of US haemodialysed patients, 25% received no iron supplementation were given i.v. iron while the peritoneal dialysis patients were maintained on oral iron if possible (Figure 20) . [3] . In the 27% of patients with overt iron deficiency defined by a TSAT <20% (~1350 patients), a quarter Taken in conjunction with Figures 23 and 24 , the data also suggest that oral iron is not as effective at of them (~340 patients) received no iron, and half of them did not receive parenteral iron. maintaining adequate iron status as i.v. iron. Although there are clearly logistical difficulties, it may be that It is gratifying to see that the combined use of oral greater use of i.v. iron is required in the peritoneal incidence of infectious diseases in this cohort sample, in the light of other published data [8] [9] [10] it was dialysis population than is being used currently.
The data in Figure 21 are somewhat difficult to interesting to look for any relationship between the chances of developing an infection in relation to the interpret. There is a suggestion that patients who received iron in all 6 months of the survey had a lower serum ferritin level. No obvious relationship existed, although more rigorous scientific data are required to proportion of adequate iron status. Patients who received no iron during the 6 months, however, seemed assess this more reliably.
In conclusion, whether the ESAM data are reassurto maintain an adequate iron status, and this is almost certainly due to the fact that patients with adequate ing or not depends on whether you are an optimist or a pessimist. The optimist would conclude that iron iron stores were not given iron supplementation rather than to the fact that patients not receiving any iron status is being monitored fairly regularly, and i.v. iron is being used frequently. The pessimist would feel that achieved adequate iron status. Also, in Figure 22 , the proportion of peritoneal dialysis patients with inad-since guidelines regarding iron management have been available for >10 years now, better results should be equate iron status and absolute iron deficiency was significantly greater than that observed for haemo-achieved. Particularly in the peritoneal dialysis population, there may be a need for greater use of i.v. iron, dialysis patients ( Figure 21 ). This again reflects the greater use of i.v. iron in the haemodialysis population. and hopefully ways can be found to solve the logistical problems associated with this. There are some additional troubling findings regarding iron management: specifically, the results from Iron management remains fundamental to any patient receiving epoetin therapy, and hopefully the cohorts of haemodialysis and peritoneal dialysis patients for which complete data on iron use are ESAM data provided in response to EBPG 6-8 will inspire us to continue our efforts to improve the clinical present for all 6 months of the survey. Of those with absolute iron deficiency and receiving no iron management of patients with renal anaemia. supplementation at month 1, 60.4% of haemodialysis patients and 63.2% of peritoneal dialysis patients were still receiving no iron 5 months later. Again, this is in References contrast to the recommendations of EBPG which suggest that most haemodialysis patients will require
